{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:50:57Z","timestamp":1792785057003,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main","id":[{"id":"https:\/\/ror.org\/04cvxnb49","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>For most people living with Human immunodeficiency virus (HIV), virus control and sufficient immune function can be achieved with polypharmacotherapy. A minority is intolerant to thereto, and drug-resistant mutants are emerging. Additionally, people living with HIV (PLWH) have significantly higher risk of cardiovascular morbidity and malignant diseases. HIV is in principle immunogenic. If T-cell depletion could be avoided immunological HIV eradication should be achievable. The \u201cBerlin patient\u201d in whom allogeneic stem cell transplantation from a CCR5\u039432\/\u039432 donor induced long-term remission without antiviral therapy raised the hope that stem cell gene therapy with CCR5-deleted autologous stem cells could provide a cure, but the strategy did not live up to expectations. We propose to test an alternative strategy, namely expression of a designer recombinase which specifically excises HIV provirus from the genome under a Tat-inducible promoter so that expression is restricted to infected cells. A cGMP-compliant manufacturing protocol and quality control strategy for this investigational medicinal product was developed, validated, and a manufacturing authorization obtained. A First-in-Human-clinical trial, testing engraftment, repopulation of peripheral specific immunity, and ability to control HIV infection without antiviral medication is in preparation. Protocols can be adapted to other stem cell gene therapies by transferring alternative lentviral cargo.<\/jats:p>","DOI":"10.1038\/s41598-026-64038-1","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T07:34:58Z","timestamp":1785828898000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of an investigational medicinal stem cell gene therapy product to attempt curing human immunodeficiency virus infection"],"prefix":"10.1038","volume":"16","author":[{"given":"Laura","family":"Weigand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Herkt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maike","family":"Voges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Beschorner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Friedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darja","family":"Karpova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Weseloh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Chemnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halvard","family":"Bonig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza","family":"Wiercinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"64038_CR1","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.3390\/cells11192968","volume":"11","author":"S Renelt","year":"2022","unstructured":"Renelt, S. et al. HIV-1 Infection of Long-Lived Hematopoietic Precursors In Vitro and In Vivo. Cells 11, 2968. https:\/\/doi.org\/10.3390\/cells11192968 (2022).","journal-title":"Cells"},{"key":"64038_CR2","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.3390\/v16071163","volume":"16","author":"TC Chou","year":"2024","unstructured":"Chou, T. C., Maggirwar, N. S. & Marsden, M. D. HIV Persistence, Latency, and Cure Approaches: Where Are We Now? Viruses 16, 1136. https:\/\/doi.org\/10.3390\/v16071163 (2024).","journal-title":"Viruses"},{"key":"64038_CR3","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.3390\/v15081732","volume":"15","author":"FET Foka","year":"2023","unstructured":"Foka, F. E. T., Mufhandu, H. T., Current & ARTs Virologic Failure, and Implications for AIDS Management: A Systematic Review. Viruses 15, 1732. https:\/\/doi.org\/10.3390\/v15081732 (2023).","journal-title":"Viruses"},{"key":"64038_CR4","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12879-022-07168-x","volume":"22","author":"A Pantke","year":"2022","unstructured":"Pantke, A. et al. The impact of regional socioeconomic deprivation on the timing of HIV diagnosis: a cross-sectional study in Germany. BMC Infect. Dis. 22, 258. https:\/\/doi.org\/10.1186\/s12879-022-07168-x (2022).","journal-title":"BMC Infect. Dis."},{"issue":"Suppl 3","key":"64038_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/hiv.12952","volume":"21","author":"M Bloch","year":"2020","unstructured":"Bloch, M., John, M., Smith, D., Rasmussen, T. A. & Wright, E. Managing HIV-associated inflammation and ageing in the era of modern ART. HIV Med. 21 (Suppl 3), 2\u201316. https:\/\/doi.org\/10.1111\/hiv.12952 (2020).","journal-title":"HIV Med."},{"key":"64038_CR6","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/COH.0000000000000755","volume":"17","author":"S Dirajlal-Fargo","year":"2022","unstructured":"Dirajlal-Fargo, S. & Funderburg, N. HIV and cardiovascular disease: the role of inflammation. Curr. Opin. HIV AIDS. 17, 286\u2013292. https:\/\/doi.org\/10.1097\/COH.0000000000000755 (2022).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"64038_CR7","doi-asserted-by":"publisher","unstructured":"Lv, T., Cao, W. & Li, T. HIV-Related Immune Activation and Inflammation: Current Understanding and Strategies. J Immunol Res 7316456 (2021). (2021). https:\/\/doi.org\/10.1155\/2021\/7316456","DOI":"10.1155\/2021\/7316456"},{"key":"64038_CR8","doi-asserted-by":"publisher","first-page":"e495","DOI":"10.1016\/S2352-3018(17)30125-X","volume":"4","author":"RU Hernandez-Ramirez","year":"2017","unstructured":"Hernandez-Ramirez, R. U., Shiels, M. S., Dubrow, R. & Engels, E. A. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV. 4, e495\u2013e504. https:\/\/doi.org\/10.1016\/S2352-3018(17)30125-X (2017).","journal-title":"Lancet HIV"},{"key":"64038_CR9","doi-asserted-by":"publisher","first-page":"507","DOI":"10.7326\/M14-2768","volume":"163","author":"MJ Silverberg","year":"2015","unstructured":"Silverberg, M. J. et al. Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study. Ann. Intern. Med. 163, 507\u2013518. https:\/\/doi.org\/10.7326\/M14-2768 (2015).","journal-title":"Ann. Intern. Med."},{"key":"64038_CR10","doi-asserted-by":"publisher","first-page":"101613","DOI":"10.1016\/j.eclinm.2022.101613","volume":"52","author":"T Yuan","year":"2022","unstructured":"Yuan, T. et al. Incidence and mortality of non-AIDS-defining cancers among people living with HIV: A systematic review and meta-analysis. EClinicalMedicine 52, 101613. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101613 (2022).","journal-title":"EClinicalMedicine"},{"issue":"Suppl 1","key":"64038_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/QAD.0000000000002602","volume":"34","author":"BA Friedland","year":"2020","unstructured":"Friedland, B. A. et al. The People Living with HIV Stigma Index 2.0: generating critical evidence for change worldwide. AIDS 34 (Suppl 1), 5\u201318. https:\/\/doi.org\/10.1097\/QAD.0000000000002602 (2020).","journal-title":"AIDS"},{"key":"64038_CR12","doi-asserted-by":"publisher","first-page":"e011453","DOI":"10.1136\/bmjopen-2016-011453","volume":"6","author":"S Rueda","year":"2016","unstructured":"Rueda, S. et al. Examining the associations between HIV-related stigma and health outcomes in people living with HIV\/AIDS: a series of meta-analyses. BMJ Open. 6, e011453. https:\/\/doi.org\/10.1136\/bmjopen-2016-011453 (2016).","journal-title":"BMJ Open."},{"key":"64038_CR13","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1056\/NEJMc2312556","volume":"390","author":"JK Dickter","year":"2024","unstructured":"Dickter, J. K. et al. HIV-1 Remission after Allogeneic Hematopoietic-Cell Transplantation. N Engl. J. Med. 390, 669\u2013671. https:\/\/doi.org\/10.1056\/NEJMc2312556 (2024).","journal-title":"N Engl. J. Med."},{"key":"64038_CR14","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41586-019-1027-4","volume":"568","author":"RK Gupta","year":"2019","unstructured":"Gupta, R. K. et al. HIV-1 remission following CCR5Delta32\/Delta32 haematopoietic stem-cell transplantation. Nature 568, 244\u2013248. https:\/\/doi.org\/10.1038\/s41586-019-1027-4 (2019).","journal-title":"Nature"},{"key":"64038_CR15","doi-asserted-by":"publisher","unstructured":"Hsu, J. et al. HIV-1 remission and possible cure in a woman after haplo-cord blood transplant. Cell 186, 1115\u20131126 e1118 (2023). https:\/\/doi.org\/10.1016\/j.cell.2023.02.030","DOI":"10.1016\/j.cell.2023.02.030"},{"key":"64038_CR16","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJMoa0802905","volume":"360","author":"G Hutter","year":"2009","unstructured":"Hutter, G. et al. Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation. N Engl. J. Med. 360, 692\u2013698. https:\/\/doi.org\/10.1056\/NEJMoa0802905 (2009).","journal-title":"N Engl. J. Med."},{"key":"64038_CR17","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41591-023-02213-x","volume":"29","author":"BO Jensen","year":"2023","unstructured":"Jensen, B. O. et al. In-depth virological and immunological characterization of HIV-1 cure after CCR5Delta32\/Delta32 allogeneic hematopoietic stem cell transplantation. Nat. Med. 29, 583\u2013587. https:\/\/doi.org\/10.1038\/s41591-023-02213-x (2023).","journal-title":"Nat. Med."},{"key":"64038_CR18","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.medj.2023.04.006","volume":"4","author":"B Bone","year":"2023","unstructured":"Bone, B. & Lichterfeld, M. Curating evidence for a cure of HIV-1 infection by hematopoietic stem cell transplantation. Med 4, 285\u2013287. https:\/\/doi.org\/10.1016\/j.medj.2023.04.006 (2023).","journal-title":"Med"},{"key":"64038_CR19","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41586-025-09893-0","volume":"650","author":"C Gaebler","year":"2026","unstructured":"Gaebler, C. et al. Sustained HIV-1 remission after heterozygous CCR5Delta32 stem cell transplantation. Nature 650, 701\u2013709. https:\/\/doi.org\/10.1038\/s41586-025-09893-0 (2026).","journal-title":"Nature"},{"key":"64038_CR20","doi-asserted-by":"publisher","first-page":"16067","DOI":"10.1038\/mtm.2016.67","volume":"3","author":"DL DiGiusto","year":"2016","unstructured":"DiGiusto, D. L. et al. Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem\/progenitor cells. Mol. Ther. Methods Clin. Dev. 3, 16067. https:\/\/doi.org\/10.1038\/mtm.2016.67 (2016).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"64038_CR21","doi-asserted-by":"publisher","first-page":"5560","DOI":"10.1093\/nar\/gkv469","volume":"43","author":"U Mock","year":"2015","unstructured":"Mock, U. et al. mRNA transfection of a novel TAL effector nuclease (TALEN) facilitates efficient knockout of HIV co-receptor CCR5. Nucleic Acids Res. 43, 5560\u20135571. https:\/\/doi.org\/10.1093\/nar\/gkv469 (2015).","journal-title":"Nucleic Acids Res."},{"key":"64038_CR22","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/nbt1410","volume":"26","author":"EE Perez","year":"2008","unstructured":"Perez, E. E. et al. Establishment of HIV-1 resistance in CD4\u2009+\u2009T cells by genome editing using zinc-finger nucleases. Nat. Biotechnol. 26, 808\u2013816. https:\/\/doi.org\/10.1038\/nbt1410 (2008).","journal-title":"Nat. Biotechnol."},{"key":"64038_CR23","doi-asserted-by":"publisher","first-page":"e2000023","DOI":"10.1002\/biot.202000023","volume":"16","author":"M Romito","year":"2021","unstructured":"Romito, M. et al. Preclinical Evaluation of a Novel TALEN Targeting CCR5 Confirms Efficacy and Safety in Conferring Resistance to HIV-1 Infection. Biotechnol. J. 16, e2000023. https:\/\/doi.org\/10.1002\/biot.202000023 (2021).","journal-title":"Biotechnol. J."},{"key":"64038_CR24","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1056\/NEJMoa1817426","volume":"381","author":"L Xu","year":"2019","unstructured":"Xu, L. et al. CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia. N Engl. J. Med. 381, 1240\u20131247. https:\/\/doi.org\/10.1056\/NEJMoa1817426 (2019).","journal-title":"N Engl. J. Med."},{"key":"64038_CR25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nbt.3467","volume":"34","author":"J Karpinski","year":"2016","unstructured":"Karpinski, J. et al. Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity. Nat. Biotechnol. 34, 401\u2013409. https:\/\/doi.org\/10.1038\/nbt.3467 (2016).","journal-title":"Nat. Biotechnol."},{"key":"64038_CR26","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ymeth.2010.06.014","volume":"53","author":"F Buchholz","year":"2011","unstructured":"Buchholz, F. & Hauber, J. In vitro evolution and analysis of HIV-1 LTR-specific recombinases. Methods 53, 102\u2013109. https:\/\/doi.org\/10.1016\/j.ymeth.2010.06.014 (2011).","journal-title":"Methods"},{"key":"64038_CR27","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1038\/s41467-019-10892-9","volume":"10","author":"JL Bessen","year":"2019","unstructured":"Bessen, J. L. et al. High-resolution specificity profiling and off-target prediction for site-specific DNA recombinases. Nat. Commun. 10, 3003. https:\/\/doi.org\/10.1038\/s41467-019-10892-9 (2019). Addendum.","journal-title":"Nat. Commun."},{"key":"64038_CR28","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10822-014-9825-0","volume":"29","author":"J Abi-Ghanem","year":"2015","unstructured":"Abi-Ghanem, J., Samsonov, S. A. & Pisabarro, M. T. Insights into the preferential order of strand exchange in the Cre\/loxP recombinase system: impact of the DNA spacer flanking sequence and flexibility. J. Comput. Aided Mol. Des. 29, 271\u2013282. https:\/\/doi.org\/10.1007\/s10822-014-9825-0 (2015).","journal-title":"J. Comput. Aided Mol. Des."},{"key":"64038_CR29","doi-asserted-by":"publisher","first-page":"8017","DOI":"10.1093\/nar\/gkae481","volume":"52","author":"J Hoersten","year":"2024","unstructured":"Hoersten, J. et al. Engineering spacer specificity of the Cre\/loxP system. Nucleic Acids Res. 52, 8017\u20138031. https:\/\/doi.org\/10.1093\/nar\/gkae481 (2024).","journal-title":"Nucleic Acids Res."},{"key":"64038_CR30","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1128\/MCB.20.2.648-655.2000","volume":"20","author":"B Zheng","year":"2000","unstructured":"Zheng, B., Sage, M., Sheppeard, E. A., Jurecic, V. & Bradley, A. Engineering mouse chromosomes with Cre-loxP: range, efficiency, and somatic applications. Mol. Cell. Biol. 20, 648\u2013655. https:\/\/doi.org\/10.1128\/MCB.20.2.648-655.2000 (2000).","journal-title":"Mol. Cell. Biol."},{"key":"64038_CR31","doi-asserted-by":"publisher","first-page":"e0298542","DOI":"10.1371\/journal.pone.0298542","volume":"19","author":"N Beschorner","year":"2024","unstructured":"Beschorner, N. et al. Preclinical toxicity analyses of lentiviral vectors expressing the HIV-1 LTR-specific designer-recombinase Brec1. PLoS One. 19, e0298542. https:\/\/doi.org\/10.1371\/journal.pone.0298542 (2024).","journal-title":"PLoS One"},{"key":"64038_CR32","doi-asserted-by":"publisher","first-page":"e1003587","DOI":"10.1371\/journal.ppat.1003587","volume":"9","author":"I Hauber","year":"2013","unstructured":"Hauber, I. et al. Highly significant antiviral activity of HIV-1 LTR-specific tre-recombinase in humanized mice. PLoS Pathog. 9, e1003587. https:\/\/doi.org\/10.1371\/journal.ppat.1003587 (2013).","journal-title":"PLoS Pathog"},{"key":"64038_CR33","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3109\/14653249.2010.529894","volume":"13","author":"K Dauber","year":"2011","unstructured":"Dauber, K. et al. Enumeration of viable CD34(+) cells by flow cytometry in blood, bone marrow and cord blood: results of a study of the novel BD stem cell enumeration kit. Cytotherapy 13, 449\u2013458. https:\/\/doi.org\/10.3109\/14653249.2010.529894 (2011).","journal-title":"Cytotherapy"},{"key":"64038_CR34","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jtct.2025.01.258","volume":"31","author":"A Giommetti","year":"2025","unstructured":"Giommetti, A. et al. Maximizing Safety and Efficacy in Hematopoietic Stem Cell Gene Therapy. Transplantation Cell. Therapy (ASCTC Meeting Abstracts). 31, 168 (2025).","journal-title":"Transplantation Cell. Therapy (ASCTC Meeting Abstracts)"},{"key":"64038_CR35","first-page":"7837","volume":"146","author":"A Giommetti","year":"2025","unstructured":"Giommetti, A. et al. An automated platform for lentiviral transduction for HSC gene therapy promotes fitness of hematopoietic stem cells combined with higher transduction efficiency. Blood (ASH Meeting Abstracts). 146, 7837 (2025).","journal-title":"Blood (ASH Meeting Abstracts)"},{"key":"64038_CR36","first-page":"157","volume":"27","author":"A Rubio Gomez","year":"2025","unstructured":"Rubio Gomez, A. et al. Toward the development of an automated manufacturing process for hematopoietic stem cell gene therapies. Cytotherapy (ISCT Meeting Abstracts). 27, 157 (2025).","journal-title":"Cytotherapy (ISCT Meeting Abstracts)"},{"key":"64038_CR37","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.jcyt.2015.04.005","volume":"17","author":"G Spohn","year":"2015","unstructured":"Spohn, G. et al. Automated CD34\u2009+\u2009cell isolation of peripheral blood stem cell apheresis product. Cytotherapy 17, 1465\u20131471. https:\/\/doi.org\/10.1016\/j.jcyt.2015.04.005 (2015).","journal-title":"Cytotherapy"},{"key":"64038_CR38","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12967-021-02810-9","volume":"19","author":"E Wiercinska","year":"2021","unstructured":"Wiercinska, E. et al. Allogeneic transplant procurement in the times of COVID-19: Quality report from the central European cryopreservation site. J. Transl Med. 19, 145. https:\/\/doi.org\/10.1186\/s12967-021-02810-9 (2021).","journal-title":"J. Transl Med."},{"key":"64038_CR39","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.3324\/haematol.2016.154740","volume":"102","author":"MR Lidonnici","year":"2017","unstructured":"Lidonnici, M. R. et al. Plerixafor and G-CSF combination mobilizes hematopoietic stem and progenitors cells with a distinct transcriptional profile and a reduced in vivo homing capacity compared to plerixafor alone. Haematologica 102, e120\u2013e124. https:\/\/doi.org\/10.3324\/haematol.2016.154740 (2017).","journal-title":"Haematologica"},{"key":"64038_CR40","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1182\/blood-2015-03-629618","volume":"126","author":"G Karponi","year":"2015","unstructured":"Karponi, G. et al. Plerixafor\u2009+\u2009G-CSF-mobilized CD34\u2009+\u2009cells represent an optimal graft source for thalassemia gene therapy. Blood 126, 616\u2013619. https:\/\/doi.org\/10.1182\/blood-2015-03-629618 (2015).","journal-title":"Blood"},{"key":"64038_CR41","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1089\/hgtb.2014.005","volume":"25","author":"N Psatha","year":"2014","unstructured":"Psatha, N. et al. Superior long-term repopulating capacity of G-CSF+plerixafor-mobilized blood: implications for stem cell gene therapy by studies in the Hbb(th-3) mouse model. Hum. Gene Ther. Methods. 25, 317\u2013327. https:\/\/doi.org\/10.1089\/hgtb.2014.005 (2014).","journal-title":"Hum. Gene Ther. Methods"},{"key":"64038_CR42","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12967-016-0826-8","volume":"14","author":"C Hummer","year":"2016","unstructured":"Hummer, C. et al. Automation of cellular therapy product manufacturing: results of a split validation comparing CD34 selection of peripheral blood stem cell apheresis product with a semi-manual vs. an automatic procedure. J. Transl Med. 14, 76. https:\/\/doi.org\/10.1186\/s12967-016-0826-8 (2016).","journal-title":"J. Transl Med."},{"key":"64038_CR43","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1089\/106161299320488","volume":"8","author":"M Schumm","year":"1999","unstructured":"Schumm, M. et al. Isolation of highly purified autologous and allogeneic peripheral CD34\u2009+\u2009cells using the CliniMACS device. J. Hematother. 8, 209\u2013218. https:\/\/doi.org\/10.1089\/106161299320488 (1999).","journal-title":"J. Hematother"},{"key":"64038_CR44","doi-asserted-by":"publisher","first-page":"114281","DOI":"10.1016\/j.addr.2022.114281","volume":"185","author":"HS Newton","year":"2022","unstructured":"Newton, H. S., Dobrovolskaia, M. A. & Immunophenotyping Analytical approaches and role in preclinical development of nanomedicines. Adv. Drug Deliv Rev. 185, 114281. https:\/\/doi.org\/10.1016\/j.addr.2022.114281 (2022).","journal-title":"Adv. Drug Deliv Rev."},{"key":"64038_CR45","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/19336950.2020.1859753","volume":"15","author":"G Tajti","year":"2021","unstructured":"Tajti, G. et al. Immunomagnetic separation is a suitable method for electrophysiology and ion channel pharmacology studies on T cells. Channels (Austin). 15, 53\u201366. https:\/\/doi.org\/10.1080\/19336950.2020.1859753 (2021).","journal-title":"Channels (Austin)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-64038-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-64038-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-64038-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:58:34Z","timestamp":1792155514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-64038-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["64038"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-64038-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"20 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this Article was revised: The Funding information section was incomplete and should have read, \"The work was supported in part by research grants from BMBF (01KG1811) and BWFG Hamburg (CombatHIV). Open Access funding enabled and organized by Projekt DEAL.\" The original article has been corrected.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NB, MV, BW and JC are employees and\/or founders of PROVIREX Genome Editing Therapies GmbH, a start-up company developing the product discussed here towards clinical application. PROVIREX holds the exclusive license for all 3 HIV-1 recombinase patents: WO 2008\/083931 A1, WO 2011\/147590 A2 and WO 2016\/034553 A1. The other authors declare no pertinent financial and personal interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"24020"}}